drugset
drugset / Trial / NCT06095388

Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA

NCT06095388 ↗

Phase 1/2 Active not recruiting 15 enrolled JCR Pharmaceuticals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase I/ II, open-label, randomized, 2-arm study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIA patients.

Timeline

Start
2023-10-04
Primary completion
2029-10-31
Completion
2029-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject JR-441 Unknown — Intravenous

Indications

mucopolysaccharidosis type 3A